OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Impact of COVID-19 in Cystic Fibrosis
Patrick A. Flume, Lisa Saiman, Bruce C. Marshall
Archivos de Bronconeumología (2021) Vol. 58, Iss. 6, pp. 466-468
Open Access | Times Cited: 13
Patrick A. Flume, Lisa Saiman, Bruce C. Marshall
Archivos de Bronconeumología (2021) Vol. 58, Iss. 6, pp. 466-468
Open Access | Times Cited: 13
Showing 13 citing articles:
Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases
Eusebi Chiner‐Vives, Rosa Cordovilla, David de la Rosa, et al.
Archivos de Bronconeumología (2022) Vol. 58, pp. 39-50
Open Access | Times Cited: 52
Eusebi Chiner‐Vives, Rosa Cordovilla, David de la Rosa, et al.
Archivos de Bronconeumología (2022) Vol. 58, pp. 39-50
Open Access | Times Cited: 52
Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
Chengyu Zhu, Zhiwei Cui, Tingting Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Chengyu Zhu, Zhiwei Cui, Tingting Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
Renate Kos, Anne H. Neerincx, Dominic Fenn, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 17
Renate Kos, Anne H. Neerincx, Dominic Fenn, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 17
Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis
Sourabh Soni, Laura Antonescu, Kaylin Ro, et al.
American Journal Of Pathology (2024) Vol. 194, Iss. 10, pp. 1807-1822
Closed Access | Times Cited: 1
Sourabh Soni, Laura Antonescu, Kaylin Ro, et al.
American Journal Of Pathology (2024) Vol. 194, Iss. 10, pp. 1807-1822
Closed Access | Times Cited: 1
Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations
Jonathan D. Cogen, Bradley S. Quon
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 4, pp. 603-611
Open Access | Times Cited: 1
Jonathan D. Cogen, Bradley S. Quon
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 4, pp. 603-611
Open Access | Times Cited: 1
SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
Carmelo Biondo, Angelina Midiri, Elisabetta Gerace, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2087-2087
Open Access | Times Cited: 6
Carmelo Biondo, Angelina Midiri, Elisabetta Gerace, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2087-2087
Open Access | Times Cited: 6
Impact of COVID-19 pandemic on health care system, work, and mental well-being of people with cystic fibrosis
R. Bhatnagar, Sarah Tecklenborg, Ricardo Segurado, et al.
Irish Journal of Medical Science (1971 -) (2023) Vol. 192, Iss. 6, pp. 2961-2968
Open Access | Times Cited: 3
R. Bhatnagar, Sarah Tecklenborg, Ricardo Segurado, et al.
Irish Journal of Medical Science (1971 -) (2023) Vol. 192, Iss. 6, pp. 2961-2968
Open Access | Times Cited: 3
The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial
Laura S. Gold, Ryan N. Hansen, Nicole Mayer-Hamblett, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 30, Iss. 1, pp. 26-33
Open Access | Times Cited: 3
Laura S. Gold, Ryan N. Hansen, Nicole Mayer-Hamblett, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 30, Iss. 1, pp. 26-33
Open Access | Times Cited: 3
Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
Teresa Fuchs, Dorothea Appelt, Helmut Ellemunter
Vaccines (2023) Vol. 11, Iss. 3, pp. 657-657
Open Access | Times Cited: 2
Teresa Fuchs, Dorothea Appelt, Helmut Ellemunter
Vaccines (2023) Vol. 11, Iss. 3, pp. 657-657
Open Access | Times Cited: 2
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)
CADTH
Canadian Journal of Health Technologies (2024) Vol. 4, Iss. 2
Open Access
CADTH
Canadian Journal of Health Technologies (2024) Vol. 4, Iss. 2
Open Access
Occurrence of COVID-19 in cystic fibrosis patients: a review
F Abolhasani, Masood Moein, Niloofar Rezaie, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access
F Abolhasani, Masood Moein, Niloofar Rezaie, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access
A percepção do impacto da Covid-19 na vida de crianças e adolescentes com fibrose cística
Danielle Portella Ferreira, Saint Clair Gomes, Mariana Cardim Novaes, et al.
Interface - Comunicação Saúde Educação (2023) Vol. 27
Open Access
Danielle Portella Ferreira, Saint Clair Gomes, Mariana Cardim Novaes, et al.
Interface - Comunicação Saúde Educação (2023) Vol. 27
Open Access
SARS‐CoV‐2 infection in children with cystic fibrosis: A cross‐sectional multicenter study in Spain. New waves, new knowledge
Pedro Mondéjar-López, Laura Moreno‐Galarraga, Cristina de Manuel Gómez, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 11, pp. 3195-3205
Open Access
Pedro Mondéjar-López, Laura Moreno‐Galarraga, Cristina de Manuel Gómez, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 11, pp. 3195-3205
Open Access
Breath of fresh insight: unraveling the evolution of our understanding of cystic fibrosis pulmonary exacerbations
Ranjani Somayaji, Bradley S. Quon
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 6, pp. 587-594
Closed Access
Ranjani Somayaji, Bradley S. Quon
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 6, pp. 587-594
Closed Access
